Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
A Pichet Binette, S Janelidze, N Cullen… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, S Janelidze, N Cullen… - Alzheimer's and …, 2023 - portal.research.lu.se
Introduction: Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, S Janelidze, N Cullen, JL Dage… - medRxiv, 2022 - medrxiv.org
INTRODUCTION Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
[PDF][PDF] Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, RJ Bateman, K Blennow - scholar.archive.org
Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical
performance Page 1 1 Confounding factors of Alzheimer’s disease plasma biomarkers and …
performance Page 1 1 Confounding factors of Alzheimer’s disease plasma biomarkers and …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
A Pichet Binette, S Janelidze, N Cullen… - Alzheimer's and …, 2023 - lup.lub.lu.se
Introduction: Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
A Pichet Binette, S Janelidze, N Cullen… - Alzheimer's & …, 2022 - discovery.ucl.ac.uk
INTRODUCTION: Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, S Janelidze, N Cullen… - … & dementia: the …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance.
P Binette, S Janelidze, N Cullen, JL Dage… - … & Dementia: the …, 2022 - europepmc.org
Methods Participants with plasma and CSF biomarkers, creatinine, body mass index (BMI),
and medical history data were included (BioFINDER-1: n= 748, BioFINDER-2: n= 421). We …
and medical history data were included (BioFINDER-1: n= 748, BioFINDER-2: n= 421). We …
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, S Janelidze, N Cullen, JL Dage… - Alzheimer's and …, 2023 - profiles.wustl.edu
Introduction: Plasma biomarkers will likely revolutionize the diagnostic work-up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …
[HTML][HTML] Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
AP Binette, S Janelidze, N Cullen, JL Dage… - … & dementia: the …, 2023 - ncbi.nlm.nih.gov
METHODS: Participants with plasma and CSF biomarkers, creatinine, body mass index
(BMI), and medical history data were included (BioFINDER-1: n= 748, BioFINDER-2: n …
(BMI), and medical history data were included (BioFINDER-1: n= 748, BioFINDER-2: n …